Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Accurate diagnosis and evaluation are the cornerstones of effective management for patients with polycythemia vera (PV). This page provides a detailed roadmap for clinicians and international patients seeking a clear understanding of the diagnostic pathway at Liv Hospital. Polycythemia vera accounts for roughly 2 % of all myeloproliferative neoplasms, and early detection can significantly improve long‑term outcomes. In the following sections we explore the clinical presentation, laboratory work‑up, genetic testing, imaging options, and ongoing monitoring strategies that together form a comprehensive diagnosis and evaluation process.
Liv Hospital’s multidisciplinary team combines expertise in hematology, pathology, radiology, and patient navigation to deliver a seamless experience for international patients. Whether you are referred for a routine blood count abnormality or present with complex thrombotic events, our structured approach ensures that every diagnostic step is performed with precision, transparency, and cultural sensitivity.
The first step in the diagnosis and evaluation of polycythemia vera is a thorough clinical assessment. Patients often present with nonspecific symptoms that can be mistaken for other conditions. Common presenting features include:
During the initial visit, clinicians document a detailed medical history, focusing on risk factors such as smoking, high altitude residence, and prior cardiovascular events. A physical examination emphasizes signs of increased red blood cell mass, such as splenomegaly or palpable liver enlargement. Vital signs, including blood pressure and oxygen saturation, are recorded to identify secondary causes of erythrocytosis.
In addition to symptom review, the assessment includes a baseline performance status using the Eastern Cooperative Oncology Group (ECOG) scale. This helps to stratify patients early and informs subsequent therapeutic decisions. At Liv Hospital, interpreter services and culturally adapted questionnaires ensure that international patients can convey their symptoms accurately, facilitating a reliable diagnosis and evaluation process.
Laboratory investigations are pivotal for confirming polycythemia vera and differentiating it from secondary erythrocytosis. The following core tests are ordered as part of the standard diagnosis and evaluation protocol:
In addition to these baseline studies, a comprehensive metabolic panel evaluates liver and kidney function, which are important for future treatment planning. Liv Hospital’s laboratory follows JCI‑accredited standards, ensuring that every result is accurate, reproducible, and delivered promptly to the treating hematologist.
For patients with borderline values, repeat testing after a 2‑week interval is recommended to confirm persistent erythrocytosis before proceeding to more invasive diagnostics. This careful diagnosis and evaluation minimizes false‑positive results and reduces patient anxiety.When laboratory findings suggest polycythemia vera, bone marrow biopsy and molecular analysis become essential components of the diagnosis and evaluation workflow. The biopsy provides histopathological confirmation, while genetic testing identifies driver mutations that are highly specific for PV.
The marrow typically shows:
These features, combined with clinical and laboratory data, satisfy the World Health Organization (WHO) criteria for PV.
Over 95 % of PV patients harbor a mutation in the JAK2 gene. The most common variant is JAK2 V617F; a smaller subset carries exon 12 mutations. Testing is performed using quantitative PCR or next‑generation sequencing (NGS). The table below summarizes the key molecular findings:
Liv Hospital’s molecular pathology laboratory adheres to international quality standards, delivering results within 48 hours. A positive JAK2 mutation, together with the clinical and laboratory criteria, finalizes the diagnosis and evaluation of polycythemia vera.
Accurate diagnosis and evaluation requires ruling out secondary erythrocytosis, which can arise from chronic hypoxia, high‑altitude living, or exogenous erythropoietin use. The following conditions are systematically evaluated:
Each potential secondary cause is investigated with targeted tests. For instance, a patient with a history of smoking may undergo a chest CT to evaluate chronic obstructive pulmonary disease (COPD), while a person with unexplained hypertension might receive renal Doppler studies. By systematically eliminating these alternatives, clinicians ensure that the final diagnosis of polycythemia vera is both accurate and defensible.
The comprehensive approach adopted at Liv Hospital integrates these exclusionary steps into a single, patient‑centered pathway, minimizing the need for repeated appointments and reducing the overall time to definitive diagnosis and evaluation.
While imaging is not required for the initial diagnosis of polycythemia vera, it plays a vital role in risk stratification and management planning. The most commonly employed modalities include:
Risk stratification incorporates age, history of thrombosis, and leukocyte count. Patients older than 60 years or with prior thrombotic events are classified as high‑risk and may require more aggressive cytoreductive therapy. Imaging findings, especially splenomegaly and evidence of thrombosis, further refine this categorization.
Liv Hospital’s radiology department utilizes state‑of‑the‑art MRI and CT scanners, and all images are reviewed by board‑certified radiologists with hematology expertise. This ensures that imaging data seamlessly integrate into the overall diagnosis and evaluation framework.
After establishing a definitive diagnosis, continuous monitoring is essential to assess treatment response, detect disease progression, and prevent complications. The following schedule is recommended for most patients:
Therapeutic goals focus on maintaining hematocrit below 45 % and controlling leukocytosis. Phlebotomy, low‑dose aspirin, and, when indicated, cytoreductive agents such as hydroxyurea are adjusted based on these monitoring parameters.
Liv Hospital offers a dedicated International Patient Services team that coordinates follow‑up appointments, arranges telemedicine consultations, and provides multilingual education materials. This patient‑centric approach guarantees that the long‑term diagnosis and evaluation of polycythemia vera remains consistent, transparent, and aligned with each individual’s health goals.
Liv Hospital combines JCI accreditation, a multidisciplinary hematology team, and a 360‑degree international patient service model. Our expertise in myeloproliferative neoplasms, coupled with cutting‑edge laboratory and imaging facilities, ensures accurate diagnosis and evaluation for polycythemia vera. International patients benefit from personalized language support, streamlined appointment coordination, and assistance with travel and accommodation, making the entire care journey smooth and stress‑free.
Ready to start your comprehensive evaluation for polycythemia vera? Contact Liv Hospital today to schedule a consultation with our hematology specialists and experience world‑class care tailored to international patients.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Patients with polycythemia vera often present with nonspecific complaints. Headache or dizziness results from increased blood viscosity, while pruritus, especially after a warm shower, is caused by histamine release from basophils. A ruddy complexion, known as plethora, reflects elevated red cell mass. Fatigue and weakness stem from the disease’s metabolic impact. Importantly, many patients have a prior thrombotic event such as deep‑vein thrombosis or pulmonary embolism, which raises suspicion for an underlying myeloproliferative neoplasm. Recognizing this constellation helps clinicians initiate the diagnostic work‑up promptly.
The diagnostic laboratory panel starts with a CBC that typically shows elevated hemoglobin (>16.5 g/dL in men, >16.0 g/dL in women) and hematocrit (>49 % men, >48 % women). A low or undetectable serum erythropoietin level helps exclude secondary causes of erythrocytosis. Iron studies are performed to rule out iron deficiency, which can mask true red cell mass; ferritin is usually normal or elevated. A peripheral blood smear may reveal increased red cell mass and occasional nucleated red cells. Additional chemistry panels assess liver and kidney function before therapy. Repeating borderline results after two weeks is recommended to confirm persistent erythrocytosis.
Molecular analysis is a cornerstone of PV diagnosis. Over 95 % of patients harbor the JAK2 V617F mutation, while 3‑5 % have exon 12 variants. These mutations are identified using quantitative PCR or next‑generation sequencing, providing a highly specific marker of clonal myeloproliferation. A positive JAK2 result, together with WHO clinical and laboratory criteria, establishes the diagnosis. Testing for CALR or MPL mutations is also performed to exclude other myeloproliferative neoplasms when JAK2 is negative.
While imaging is not needed for the initial PV diagnosis, it becomes important for staging and management. Abdominal ultrasound evaluates splenomegaly; a spleen larger than 13 cm suggests higher disease burden. CT angiography detects pulmonary emboli or deep‑vein thrombosis, which are common complications. Bone‑marrow MRI can assess fibrosis progression, and echocardiography screens for high‑output cardiac failure. These studies help classify patients into low‑ or high‑risk groups, guiding therapeutic intensity.
Long‑term follow‑up aims to keep hematocrit below 45 % and control leukocytosis. Every three months, a CBC with differential monitors red cell mass and leukocyte count. Semi‑annual labs include serum erythropoietin, iron studies, and, for patients on cytoreductive therapy, JAK2 allele burden to gauge treatment response. Annually, a bone‑marrow biopsy may be performed if there is clinical suspicion of fibrosis. Imaging is repeated as needed when new thrombotic symptoms or splenomegaly progression occur. This structured protocol enables early detection of disease evolution and therapy adjustment.
International patients benefit from a 360‑degree support model at Liv Hospital. Professional interpreters are available for over 30 languages, ensuring accurate symptom reporting. Culturally adapted questionnaires capture relevant medical history while respecting patient background. The International Patient Services team coordinates appointments, arranges tele‑medicine follow‑ups, and supplies multilingual education materials. All diagnostic steps—from laboratory testing to imaging—are streamlined to minimize travel and reduce time to definitive diagnosis, delivering a patient‑centered experience.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75